Hyperfine, Inc. Class A Common Stock
HYPRHyperfine, Inc. is a medical technology company specializing in portable, point-of-care MRI systems. Known for its Hyperfine Swoop device, the company aims to make advanced imaging more accessible, affordable, and easier to operate in various healthcare settings. Founded to improve patient care through innovative imaging solutions, Hyperfine focuses on decentralized healthcare and rapid diagnostics.
Company News
AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, ...
Hyperfine reported Q2 2025 results with $2.7 million revenue, 26% sequential increase, and eight system sales. The company achieved FDA clearances, expanded gross margins to 49.3%, and reduced cash burn by 19%, projecting 10-20% revenue growth for the year.
Hyperfine's Swoop system has shown promising results in a study on its ability to quickly assess stroke patients and guide treatment decisions. The study, part of the larger ACTION PMR study, found the Swoop system to be a reliable tool for enabling critical stroke treatment choices in urgent care settings.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 8.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
